Quality of life experience after neoadjuvant chemotherapy in HER2-positive breast cancer patients: a focus group study

Quality of life experience after neoadjuvant chemotherapy in HER2-positive breast cancer patients: a focus group study - Focus group TRAIN-2: quality of life.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49288

Enrollment

Registered

2020-02-20

Start date

2019-12-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer mamma carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Signed informed consent * * 18 years * Treated in the TRAIN-2 study for stage II or III HER2-positive breast cancer at the NKI * Willing and being able to fill in a questionnaire * Willing to speak about and discuss different domains of HRQoL * Proficient in Dutch

Exclusion criteria

Exclusion criteria: * Evidence of breast cancer recurrence / second primary cancer * History of severe psychiatric illness or dementia

Design outcomes

Primary

Measure	Time frame
health-related quality of life experience	—

Countries

Netherlands

Outcome results